What is the role of becaplermin in the treatment of pressure injuries (pressure ulcers)?

Updated: Mar 26, 2020
  • Author: Christian N Kirman, MD; Chief Editor: John Geibel, MD, MSc, DSc, AGAF  more...
  • Print

The recombinant human platelet-derived growth factor becaplermin has been approved by the US Food and Drug Administration (FDA) for the treatment of lower-extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond. Studies are underway to explore the possibility of expanding its approved indications to include other wounds. Other growth factors also are being evaluated for use in human clinical settings.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!